We have demonstrated that the combination of sub-optimal concentrations of PI3K/mTOR, pan-PI3K or mTOR ATP-competitive inhibitors and everolimus can achieve synergistic inhibition of the proliferation of human breast cancer cells in vitro. This evidence concerns the gene MTOR and breast carcinoma.